Which Imaging Modality Is Superior for Prediction of Response to Neoadjuvant Chemotherapy in Patients with Triple Negative Breast Cancer?

Table 1

Patient and tumor characteristics of 148 patients with 151 triple negative breast cancers treated with neoadjuvant chemotherapy between 2000 and 2010.

Characteristic	𝑁 = 148/151* (%)
Age
<50	93 (62)
≥50	55 (38)
Race
Caucasian	86 (58)
African-American	57 (39)
Other	5 (3)
Clinical T stage
T1	22 (15)
T2	73 (48)
T3	47 (31)
Unknown	9 (6)
Nuclear grade
Grade 1	2 (1)
Grade 2	16 (11)
Grade 3	125 (83)
Unknown	8 (5)
Clinical N status
N0	62 (41)
N1	63 (41)
N2	10 (7)
N3	9 (6)
Unknown	7 (5)
Clinical stage
1	10 (7)
2	83 (55)
3	45 (30)
Unknown	13 (8)
Pathologic stage
0^#	38 (25)
1	26 (17)
2	50 (33)
3	37 (25)
Unknown	0 (0)
Neoadjuvant regimen
Taxane-based	129 (87)
Nontaxane^$	19 (13)
Surgical intervention
BCT	83 (55)
Mastectomy	68 (45)

BCT: breast conservation therapy.
^∗𝑁=148 for patient characteristics (age, race, and neoadjuvant regimen utilized) and 𝑁=151 for all tumor characteristics and type of surgical intervention.
^#Pathologic Stage 0 includes 33 cases with yT0N0 and 5 cases with yTisN0 final pathology.
^$Nontaxane regimens included cisplatin- and epirubicin-based regimens.